IBM faces fraud probe after 25% stock plunge on Z shortfall

Bleichmar Fonti & Auld opened a securities fraud probe into IBM after its stock plunged 25 percent on July 14, erasing $68 billion.

"IBM revealed that it had 'faltered' and 'did not adapt and move quickly enough' so that 'numerous large deals failed to close on the timelines we expected,'" the law firm said in its investigation notice.

On July 14, IBM reported Q2 revenue growth of just 1 percent, down from the 5-plus percent projected in April. Infrastructure revenue swung from plus 15 percent in Q1 to minus 7 percent, while IBM Z revenue that rose 51 percent in the first quarter fell short in Q2. CEO Arvind Krishna attributed the miss to customer capital expenditure reprioritization. The stock fell over $75 in intraday trading to close at $217.07.

The $68 billion market cap loss has drawn parallel probes from Pomerantz LLP, Glancy Prongay Wolke & Rotter LLP, and Levi & Korsinsky LLP. Management expects two-thirds to three-quarters of the slipped deals to close within six months, but the investigation will test whether those risks were adequately disclosed before the stock price correction.

The investigation centers on whether IBM misrepresented the pace of securing new business deals and the strength of its IBM Z product outlook. IBM Z is the company's mainframe platform used for AI acceleration, end-to-end encryption, and high-throughput transaction processing workloads. In April, executives had described the start of the year as a "record start" for the z17 product, with IBM Z revenues rising 51 percent in Q1.

Generative AI accounted for approximately 50 percent of signings in Q2, but it failed to offset the decline in traditional transaction processing revenues. The concentration risk within IBM's Transaction Processing segment remains a critical vulnerability, as the sharp reversal from 51 percent growth in Q1 to a reported shortfall in Q2 illustrates the fragility of forward-looking statements when dependent on large, discrete deals.

BFA has recovered over $900 million in value from Tesla's board of directors and $420 million from Teva Pharmaceutical Industries. The firm represents shareholders on a contingency fee basis.

The investigation outcome could influence how IBM discloses large-deal timing risks in future guidance. Investors will watch for additional disclosures from the company and the progress of the parallel probes by Pomerantz and other firms. The gap between IBM's optimistic April guidance and the July actuals highlights the volatility inherent in its enterprise software cycles, where large-deal timing can swing quarterly results by billions of dollars.

This article is for informational purposes only and does not constitute investment advice.